ROCKVILLE, Md.-- ( BUSINESS WIRE )--Immunomic Therapeutics, Inc., ("ITI"), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based . ITI granted Japanese animal health company, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan) an exclusive license to develop and commercialize its investigational DNA vaccine for canine atopic dermatitis and other companion animal allergies. immunomic therapeutics crunchbase - xarxacatala.cat News Releases | PharmaJet This approach could put UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. Immunomic Therapeutics Receives FDA Fast Track Designation for ITI-3000 Should we find that your skills and experience match our position needs, a Immunomic Therapeutics, Inc. representative will contact you to discuss the opportunity. Rockville, Maryland, 20850, United States. We have significant capabilities in molecular biology, including nucleic acid vaccine design, immunology, and tumor mouse modeling. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. Glioblastoma Multiforme (GBM) - Immunomic Therapeutics ITI-1000 is being tested in a randomized, blinded, and placebo-controlled phase 2 study in patients with newly-diagnosed glioblastoma (GBM) that is anticipated to close in 2022. GBM patients white blood cells are removed, matured into dendritic cells and vaccinated against the pp65 viral protein, then returned to the patient. Immunomic Therapeutics considers applicants for all positions without regard to race, color, creed, religion, ancestry, national origin, age, gender identity, sex, marital status, sexual orientation, physical or mental disability, use of a guide dog or service animal, military/veteran status, citizenship status, basis of genetic information, or any other group protected by law. ITI-2000 provides an UNITE platform address for HPV+ cancers. J Biol Chem. ITI-2000 provides an UNITE platform address for HPV+ cancers. Immunomic Therapeutics, Inc. announced today that it has assumed sponsorship of the Investigational New Drug (IND) application for ITI-1000 from the University of Florida (UF). Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. 1K followers 500+ connections. Careers - Immunomic Therapeutics Immunomic Therapeutics Appoints Vice President, Cell Therapy Company: Melissa Kemp Immunomic Therapeutics Mkemp@immunomix.com 301-968-3501 Media: Amy Conrad Juniper Point amy@juniper-point.com 858-366-3243 Contacts ITI-1001 represents an off-the-shelf cancer immunotherapy approach that leverages ITIs proprietary UNITE platform to target CMV-associated antigens (pp65, IE-1 & gB) in Newly-Diagnosed Glioblastoma Multiforme (GBM).The primary mechanism of action of ITI-1001 is to enable specific presentation of the antigens via the lysosome mediated pathway in the antigen presenting cells (APC). UNITE is a groundbreaking approach to vaccine development that has been applied to create vaccine candidates for rabies, yellow fever, dengue fever, hepatitis C and SARS, a relative to the SARS-CoV-2 coronavirus. immunomic therapeutics crunchbase. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. 438 followers 429 connections. Immunomic Therapeutics Strengthens Leadership Team with Appointment of It is important to note that, while the mechanism of lysosomal targeting appears to focus on enhancing presentation of antigen to CD4+ T cells and producing a Th1 type CD4+ T cell response (an aspect missing in other platforms), the UNITE platform, as a whole, is believed to induce a broad immune response and can result in enhanced CD8+ T cell responses as well. Contacts ITI Company Contact: Melissa Kemp mkemp@immunomix.com 301-968-3501 ITI Media Contact: Melody Carey mcarey@rxir.com 917-322-2571 ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products that are aimed to improve the quality of life of cancer patients. pipeline of metabolic regulators preferentially targeting the cellular metabolism of drug-resistant cancer subpopulations and immuno-suppressors of anti-cancer effector T cells. Mohan Karkada - Director of Research and Development - LinkedIn ITI-ID Candidate Multiple infectious diseases. 2003 Sep 26;278(39):37926-36. ITI is also collaborating with academic centers and biotechnology companies to study the use of UNITE in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. Concurrent with the financing, five (5) members from HLB Co., LTD will be joining the Immunomic Therapeutics Board of Directors. Immunomic Therapeutics - Crunchbase Company Profile & Funding Prior to joining ITI, Mr. Stamper held director roles in manufacturing at Kite Pharma, a global biopharmaceutical company whose focus is cell therapy to treat and cure cancer. Founded Date 2015. 301-968-3501 Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. / Oct 13, 2015. Prior to that, Mr. Stamper held positions of increasing responsibility in various operational areas at Lonza Pharmaceuticals and Biotechnology, AstraZeneca Biologics and Eli Lilly & Company. Join to follow . Types of diversity represented in an organization, specifically of those who are founding members, currently the CEO, or have check-writing abilities in an investment firm. Find More Contacts for Immunic Therapeutics, Edit Lists Featuring This Company Section, Immunic, Inc. GBM patients white blood cells are removed, matured into dendritic cells and vaccinated against the pp65 viral protein, then returned to the patient. Brians specific and deep knowledge of cell therapy manufacturing and operations will be invaluable as we prepare for phase 3 testing of ITI-1000, our lead dendritic cell therapy for the treatment of glioblastoma multiforme (GBM).. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. 301-968-3501, ITI Media: What is health insurance like at Immunomic Therapeutics. A successful transition from cell to cell-free therapy would provide broad validation to the ITI pDNA pipeline. The Company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease, and allergy. Our Company Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE ), which is designed to utilize the body's natural biochemistry to develop vaccines that generate broad immune responses Read More Our Focus ITI is . Frans broad experience and deep knowledge in regulatory affairs will be a tremendous asset during a critical time for ITI, as we continue our interactions with the FDA and other key regulatory agencies regarding our clinical programs, stated William Hearl, Ph.D., Immunomic Therapeutics Chief Executive Officer. Immunomic Therapeutics, Inc. | 2,335 followers on LinkedIn. It is interesting to note that the emerging market of brain tumor includes budding gene therapies, i.e., Ofranergene obadenovec (VBL Therapeutics) and Ad-RTS-hIL-12 in combination with Veledimex . -Proceeds to support acceleration of Phase II clinical trial for GBM, advancement of pipeline, including development of COVID-19 vaccine candidate and expansion of opportunities for its UNITE nucleic acid platform-. ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products . Company Type For Profit. The company believes this approach may harness the bodys immune system to recognize, attack and destroy tumor cells that express CMV, which is over-expressed in GBM. The company is developing three small molecule products; its lead development program, IMU-838, a selective . Prior to her role at BTG, she held senior regulatory positions at a variety of companies specializing in therapeutics for oncology, respiratory, neurology, regenerative medicine, orthopedics and cardiovascular disease including Life Cell Corporation (Allergan), Alphatec Spine, Covidien (Medtronic), Lumenis LTD, and C.R. Companies - Johns Hopkins Technology Ventures Immunomic Therapeutics Announces Presentation on Nucleic Acid-Based Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. We believe that these early clinical studies may provide a proof of concept for UNITE in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. We provide a professional and challenging work environment . Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. Senior Scientist/Scientist II, Formulation Development. ITI Media: Ms. Harrison earned a Bachelor of Science in Biochemistry from San Diego State University. Melissa Kemp Mr. Stamper holds a Master of Biotechnology Enterprise and Entrepreneurship Degree (MBEE) from Johns Hopkins University, a Master of Science Degree in Biologics Engineering from Purdue University, and a Bachelor of Science Degree in Biochemistry from Indiana University. Work Here? Immunomic Therapeutics investigational UNITEplatform is founded in a combination of complementary technologies and capabilities: ITIs proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. Amy Conrad November 30, 2021, 7:01 PM UTC. ITI granted Japanese animal health company, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan) an exclusive license to develop and commercialize its investigational DNA vaccine for canine atopic dermatitis and other companion animal allergies. Immunomic Therapeutics - Overview, News & Competitors | ZoomInfo.com A successful transition from cell to cell-free therapy would provide broad validation to the ITI pDNA pipeline. In addition to TH1 response, we also observe antigen specific antibodies indicative of TH2 response further enhancing the anti-tumor potential of this vaccine.ITI-1001 presents an alternative for patients that missed the treatment window for other therapies or that cannot produce enough cells to start cell therapy manufacturing (~30% of patients). We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. Very family oriented. ITI is using the UNITE platform to develop vaccines against various infectious diseases, SARS-CoV-2 (COVID-19) among them. While induction of tumor-reactive CD8+ T cells is a major goal of cancer therapy, CD4+ T cells provide essential support to CD8+ T cells by promoting their expression of cytotoxic effector molecules and increasing their migratory capacity. Juniper Point SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. The foundation of a successful company is only as strong as the quality of its employee team. The company's immunomodulation platform, LAMP-Vax, enables nucleic acid immunotherapy (DNA or RNA) to utilize the body's natural . 15010 Broschart Road Suite 250. The primary mechanism of action of ITI-1000 is to generate a T cell-mediated immune response against malignant glial cells expressing the CMV pp65 protein. Immunomic Therapeutics to Present at Biotech Showcase 2023, PharmaJet Partner Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer, ITI Receives FDA Fast Track Designation for ITI-3000, ITI Announces Presentation on Nucleic Acid-Based UNITE Vaccine Platform at Vaccines Summit 2022. Companies. Su Y et al., CryJ-LAMP DNA Vaccines for Japanese Red Cedar Allergy Induce Robust Th1-Type Immune Responses in Murine Model. ITI-3000 is being tested in a Phase 1, open label, First in Human (FIH) study to evaluate the safety, tolerability, and immunogenicity of 4 mg of ITI-3000 in patients with Merkel polyomavirus-positive Merkel cell carcinoma (MCC). ITI Company: ITIs lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy. This day-long event includes an Advocacy Summit Liked by Priscilla Fussell But a few things must happen first. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent. Coordinates: 245831.9N 1213154.0E. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. ITI-1001 is an alternative, cell-free approach to treating GBM. Arruda L.B., et al., Dendritic Cell-Lysosomal-Associated Membrane Protein (LAMP) and LAMP-1-HIV-1 Gag Chimeras Have Distinct Cellular Trafficking Pathways and Prime T and B Cell Responses to a Diverse Repertoire of Epitopes. Vaccine technology developed at Johns Hopkins could lead to - Hub Be sure to include your name, the Job Code of the job you are interested in, and the accommodation you are seeking. Bard (Becton, Dickinson and Company). Background. 2015 Mar 19;519(7543):366-9. ImmunoMet Therapeutics is a biopharmaceutical company that develops and commercializes oncology products for cancer patients. Nature. Immunic Therapeutics - Crunchbase Company Profile & Funding View contacts for Immunic Therapeutics to access new leads and connect with decision-makers. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. Stemming from our UNITE Platform, Immunomic Therapeutics has developed a robust and deep pipeline focused on immunotherapeutics with an emphasis in treating and preventing many oncology indications by leveraging specific characteristics of a type of antigen. CONTACT - MiNA Therapeutics | RNA Activation While the presence of the CMV pp65 antigen itself is expected to induce a general effector T cell response, fusion of the antigen to Lysosomal Associated Membrane Protein (LAMP) is intended to compel processing of the antigen through a pathway that presents antigens specifically to CD4+ T cells and results in a robust Th1- type response (Arruda, 2006). The company is developing three small molecule products; its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of. You are here: hackberry allergy symptoms; 49ers paying players under the table; immunomic therapeutics crunchbase . ITI-1000 is currently being investigated in a Phase 2 ATTAC-II trial at UF and Duke. Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. Glassdoor gives you an inside look at what it's like to work at Immunomic Therapeutics, including salaries, reviews, office photos, and more. Team - Immunomic Therapeutics Company profile for HLB Co. Ltd. including key executives, insider trading, ownership, revenue and average growth rates. The Company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease, and allergy. Headquarters Location. Ms. Harrison brings to the company more than 30 years of experience in global regulatory strategies and submissions, interactions, intelligence and advocacy. Animal Health All. Pays for all health and welfare insurance premiums 100%. Immunomic Therapeutics, Inc. As a result, a robust T cell response by both CD4+ and CD8+ T cells is expected to drive antitumor activity of this product. Harnessing the immune system to achieve deep and durable clinical responses in cancer. Of special note are the following publications: To browse the literature, please see the curated list at PubMed. ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP (Lysosome Associated Membrane Protein)-mediated nucleic acid-based immunotherapy, today announced the appointment of Frances Harrison as Senior Vice President, Regulatory Affairs. If you enjoy the challenge that goes naturally with being part of a high growth company, then a career with Immunomic Therapeutics may be just for you. Innovative Cellular Therapeutics (ICT) | LinkedIn Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. All content is posted anonymously by employees working at Immunomic Therapeutics. Immunomic Therapeutics Announces Close of $61.3M Financing This employer has not claimed their Employer Profile and is missing out on connecting with our community. ITI-ID Candidate Multiple infectious diseases. ITI maintains its headquarters in Rockville, Maryland. As a result, we make a significant investment in our employees through our Compensation, Health and Wellness, Retirement and Disability and Career Development programs. The work and relationships that Louise has fostered over the years position us for successful meetings in the future and I look forward to contributing meaningfully to the companys future regulatory interactions to further advance ITIs development programs utilizing the innovative and proprietary UNITE technology platform.. Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. Our goal is to overcome the limitations of current immuno-oncology therapies by . Due to the volume of inquiries received, we regret that we cannot contact all applicants personally. The antigens mainly elicits TH1 response leading to cytokine release, development of cytotoxic CD8 T cells and memory CD4 T cells. Today, Brian Stamper, VP, Immunomic Therapeutics, will participate at #MTC's Annapolis Day 2023. SaaS, Android, Cloud Computing, Medical Device). 2020 Immunomic Therapeutics, Inc. All Rights Reserved. We believe that these early clinical studies may provide a proof of concept for UNITE in cancer, and if successful, set the stage for future studies, including combinations in this tumor type and others. The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product.ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers. You can also compare prices and book all best hotels in New Taipei City with one-stop booking service on Trip.com. Announces Proposed Public Offering of Common Stock, Northeastern US Companies With Fewer Than 1000 Employees (Top 10K), Companies With Fewer Than 100 Employees (Top 10K), United States Companies that Exited (Top 10K), Greater New York Area Biotechnology Companies. Hershey, PA & Rockville, MD and Tokyo, Japan. Seed, Series A, Private Equity), Alternate or previous names for the organization, Whether an Organization is for profit or non-profit, General contact email for the organization. Teri Heiland - Chief Scientific Officer (CSO) - Immunomic Therapeutics January 30, 2015 - Immunomic Therapeutics, Inc. ("Immunomic Therapeutics "), a company developing next generation vaccines based on the LAMP-vax platform, and Astellas Pharma Inc. ("Astellas") today announced they have entered into an exclusive license agreement for Japan to . With more than 6 years of experience in the field of cancer metabolism and immunometabolism, ImmunoMet has developed a comprehensive. For consideration, please send your company information, a copy of your standard search agreement, and references to: careers@immunomix.com. 15010 Broschart Dr., Suite 110, Rockville, MD 20850. 2017 Apr 15;23(8):1898-1909. For more information, please visit www.immunomix.com. 2017 Jun 12:1-10. Chinatrust Executive House Hsin-Tien-New Taipei City Updated 2022 Room Immunomic Therapeutics' continued investment in Process Development provides value in several ways. January 04, 2023 07:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy, announced today that, Vaccine exclusively delivered with the PharmaJet StratisNeedle-free Injection System December 13, 2022 11:00 AM Eastern Standard Time GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet, a company that engineers precision delivery systems that overcome, November 08, 2022 08:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held clinical-stage biotechnology company pioneering the development of LAMP-mediated nucleic acid-based immunotherapy, today announced, October 10, 2022 09:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today. ITI-3000 is a plasmid DNA vaccine targeting the large T antigen (LT) of Merkel cell polyomavirus (MCPyV). UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy, and autoimmune diseases. We are delighted to welcome Brian to the Immunomic team, said William Hearl, Ph.D., Immunomic Therapeutics Chief Executive Officer. Founders Sungwuk Kim. immunomic therapeutics crunchbase Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal . Preclinical research data is currently being developed to explore whether the UNITE platform may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. Immunomic Therapeutics Assumes Sponsorship of ATTAC II IND - Duke OTC Active, Closed, Last funding round type (e.g. Description. Hope versus experience in glioblastoma | Evaluate You will receive a reply to confirm the receipt of your application. The therapy was developed using ITIs proprietary UNITE (UNiversal Intracellular Targeted Expression) platform. Immunomic Therapeutics Announces Open Enrollment for RENEW Clinical At ITI, our success is based in great part on our ability to attract and retain the best, creative, talented, motivated and productive employees throughout our organization. Chief Scientific Officer (CSO) Immunomic Therapeutics, Inc. Jun 2019 - Present3 years 9 months. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported.